MIPS Accelerator Certification

The MIPSAccelerator v5.0.0 Modular EHR, InfoGard Certificate #IG-3478-17-0004 (cert. date January 23, 2017),  meets ONC 2015 certified EHR requirements for ambulatory settings for all EP electronic reporting measures.  Access to data requires paying for the optional QM Accelerator service as specified in a Service Agreement. There are no additional contractual limitations. There are no additional cost limitations.  Access to QRDA 1 files requires a login to the Company’s HIPAA compliant Box account. There are no additional technical limitations.

This Health IT Module is 2015 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. View our certification here. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.

Supported Measures

As an ONC Certified HIT, we are certified to report on all 64 electronic clinical quality measures. Our application calculates the best quality score for each clinician, thereby putting your best foot forward and qualifying you for the highest Merit-based Incentive Payment System score possible.

The 64 quality measures are:

  • CMS2v5: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
  • CMS22v4: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
  • CMS50v4: Closing the referral loop: receipt of specialist report
  • CMS52v4: HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis
  • CMS56v4: Functional Status Assessment for Hip Replacement
  • CMS61v5: Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL-C) Test Performed
  • CMS62v4: HIV/AIDS: Medical Visit
  • CMS64v5: Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)
  • CMS65v5: Hypertension: Improvement in Blood Pressure
  • CMS66v4: Functional Status Assessment for Knee Replacement
  • CMS68v5: Documentation of Current Medications in the Medical Record
  • CMS69v4: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
  • CMS74v5: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists
  • CMS75v4: Children Who Have Dental Decay or Cavities
  • CMS77v4: HIV/AIDS: RNA Control for Patients with HIV
  • CMS82v3: Maternal Depression Screening
  • CMS90v5: Functional Status Assessment for Complex Chronic Conditions
  • CMS117v4: Childhood Immunization Status
  • CMS122v4: Diabetes: Hemoglobin A1c Poor Control
  • CMS123v4: Diabetes: Foot Exam
  • CMS124v4: Cervical Cancer Screening
  • CMS125v4: Breast Cancer Screening
  • CMS126v4: Use of Appropriate Medications for Asthma
  • CMS127v4: Pneumonia Vaccination Status for Older Adults
  • CMS128v4: Anti-depressant Medication Management
  • CMS129v5: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
  • CMS130v4: Colorectal Cancer Screening
  • CMS131v4: Diabetes: Eye Exam
  • CMS132v4: Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
  • CMS133v4: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
  • CMS134v4: Diabetes: Urine Protein Screening
  • CMS135v4: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
  • CMS136v5: ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
  • CMS137v4: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
  • CMS138v4: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
  • CMS139v4: Falls: Screening for Future Fall Risk
  • CMS140v4: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
  • CMS141v5: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
  • CMS142v4: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
  • CMS143v4: Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
  • CMS144v4: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
  • CMS145v4: Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)
  • CMS146v4: Appropriate Testing for Children with Pharyngitis
  • CMS147v5: Preventive Care and Screening: Influenza Immunization
  • CMS148v4: Hemoglobin A1c Test for Pediatric Patients
  • CMS149v4: Dementia: Cognitive Assessment
  • CMS153v4: Chlamydia Screening for Women
  • CMS154v4: Appropriate Treatment for Children with Upper Respiratory Infection (URI)
  • CMS155v4: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
  • CMS156v4: Use of High-Risk Medications in the Elderly
  • CMS157v4: Oncology: Medical and Radiation – Pain Intensity Quantified
  • CMS158v4: Pregnant women that had HBsAg testing
  • CMS159v4: Depression Remission at Twelve Months
  • CMS160v4: Depression Utilization of the PHQ-9 Tool
  • CMS161v4: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
  • CMS163v4: Diabetes: Low Density Lipoprotein (LDL) Management
  • CMS164v4: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
  • CMS165v4: Controlling High Blood Pressure
  • CMS166v5: Use of Imaging Studies for Low Back Pain
  • CMS167v4: Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
  • CMS169v4: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
  • CMS177v4: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
  • CMS179v4: ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range
  • CMS182v5: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PQRS Accelerator Certification

This EHR Module is 2014 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services. 

The PQRS Accelerator v4.1.0 Modular EHR, Infogard Certificate #IG-3478-15-0065 (cert. date 12/23/2015), (required software: Google Chrome), meets ONC 2014 certified EHR requirements for ambulatory settings for all electronic reporting measures. Access to data requires paying for the Monthly Reporting Tool as specified in a Service Agreement.

Supported Measures

As an ONC Certified HIT, we are certified to report on all 64 electronic clinical quality measures. Because we file your data electronically, the same measures used for PQRS are also used for the Value Based Payment Modifier (VBM) program and the EHR Incentive Program eCQMs. We file data for all 3 programs at the same time, so the reporting requirements for each are satisfied.

Our application calculates the best quality score for each clinician, thereby putting your best foot forward and qualifying you for the highest Value Based Payment Modifier incentive payment possible.

The 64 quality measures are:

  • CMS2v4: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
  • CMS22v3: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
  • CMS50v3: Closing the referral loop: receipt of specialist report
  • CMS52v3: HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis
  • CMS56v3: Functional Status Assessment for Hip Replacement
  • CMS61v4: Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL-C) Test Performed
  • CMS62v3: HIV/AIDS: Medical Visit
  • CMS64v4: Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)
  • CMS65v4: Hypertension: Improvement in Blood Pressure
  • CMS66v3: Functional Status Assessment for Knee Replacement
  • CMS68v4: Documentation of Current Medications in the Medical Record
  • CMS69v3: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
  • CMS74v4: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists
  • CMS75v3: Children Who Have Dental Decay or Cavities
  • CMS77v3: HIV/AIDS: RNA Control for Patients with HIV
  • CMS82v2: Maternal Depression Screening
  • CMS90v4: Functional Status Assessment for Complex Chronic Conditions
  • CMS117v3: Childhood Immunization Status
  • CMS122v3: Diabetes: Hemoglobin A1c Poor Control
  • CMS123v3: Diabetes: Foot Exam
  • CMS124v3: Cervical Cancer Screening
  • CMS125v3: Breast Cancer Screening
  • CMS126v3: Use of Appropriate Medications for Asthma
  • CMS127v3: Pneumonia Vaccination Status for Older Adults
  • CMS128v3: Anti-depressant Medication Management
  • CMS129v4: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
  • CMS130v3: Colorectal Cancer Screening
  • CMS131v3: Diabetes: Eye Exam
  • CMS132v3: Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
  • CMS133v3: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
  • CMS134v3: Diabetes: Urine Protein Screening
  • CMS135v3: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
  • CMS136v4: ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
  • CMS137v3: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
  • CMS138v3: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
  • CMS139v3: Falls: Screening for Future Fall Risk
  • CMS140v4: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
  • CMS141v4: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
  • CMS142v3: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
  • CMS143v3: Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
  • CMS144v3: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
  • CMS145v3: Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)
  • CMS146v3: Appropriate Testing for Children with Pharyngitis
  • CMS147v4: Preventive Care and Screening: Influenza Immunization
  • CMS148v3: Hemoglobin A1c Test for Pediatric Patients
  • CMS149v3: Dementia: Cognitive Assessment
  • CMS153v3: Chlamydia Screening for Women
  • CMS154v3: Appropriate Treatment for Children with Upper Respiratory Infection (URI)
  • CMS155v3: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
  • CMS156v3: Use of High-Risk Medications in the Elderly
  • CMS157v3: Oncology: Medical and Radiation – Pain Intensity Quantified
  • CMS158v3: Pregnant women that had HBsAg testing
  • CMS159v3: Depression Remission at Twelve Months
  • CMS160v3: Depression Utilization of the PHQ-9 Tool
  • CMS161v3: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
  • CMS163v3: Diabetes: Low Density Lipoprotein (LDL) Management
  • CMS164v3: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
  • CMS165v3: Controlling High Blood Pressure
  • CMS166v4: Use of Imaging Studies for Low Back Pain
  • CMS167v3: Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
  • CMS169v3: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
  • CMS177v3: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
  • CMS179v3: ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range
  • CMS182v3: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control